AZD 2423 / AstraZeneca - LARVOL DELTA

Radiolabeling and Preliminary In Vivo Evaluation of the Candidate CCR2 Targeting PET Radioligand [11C]AZD2423. (PubMed, Pharmaceuticals (Basel)) - "Altogether, [11C]AZD2423 shows potential as a PET radioligand for the in vivo visualization of CCR2 expression in tissues outside the brain and may also serve as a lead compound for the further development of a CCR2 PET radioligand suitable for brain imaging."

Journal • Preclinical • CCR2

Radiolabeling and preliminary in vivo evaluation of the candidate CCR2 targeting PET radioligand [11C]AZD2423 (SNMMI 2024) - "Radiolabeling of [11C]AZD2423 with [11C]CO was successfully accomplished. [11C]AZD2423 is a new promising PET imaging biomarker for in vivo visualization of CCR2 expression in the periphery."

Preclinical • Cardiovascular • CCR2

Added to the pipeline for the indication: COPD (Corporate website) - AZD 2423 / AstraZeneca

Corporate Pipeline Update

A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia (Pain) - P2, N=133; NCT01200524; PMID: 23523116; Sponsor: Astra Zeneca; "The change of the NRS average pain score was not significantly different between treatment groups (AZD2423 20mg -1.54; AZD2423 150mg -1.53; placebo -1.44). There were trends towards larger reduction of NPSI total score and NPSI subscores for paroxysmal pain and paresthesia/dysesthesia by AZD2423 150mg compared to placebo."

P2 data • Pain

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P2a; N=71; Completed; Sponsor: AstraZeneca; N=44 ➔ 71

Clinical • Enrollment change

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P2a; N=71; Completed; Sponsor: AstraZeneca; Active, not recruiting ➔ Completed

Clinical • Trial completion